BioStem Technologies Receives 5 Patents for Placental Allografts
The 4 US and 1 European patents cover the design and manufacturing of the company's placental therapies. The company is targeting various applications across orthopedics, urology, and wound care.
BioStem Technologies, a Florida-based regenerative biotech company, announced it has received 4 US and 1 European patent covering the product design and manufacturing of its human placental allografts.
The company has designed a proprietary manufacturing process called BioRetain®, which they say is gentle, minimally invasive, preserves the natural integrity of amniotic tissue, and optimizes retention of growth factors and cytokines found in native tissue. It appears they are targeting various applications, including orthopedics, urology, spine (facet pain), women’s health, and wound care.
If you’re curious, they have a great company presentation PDF seen here.
The patents in the USA cover:
- No. 30/010,024: FENESTRATED HUMAN PLACENTAL ALLOGRAFT
The patent is directed to fenestrated human placental allograft designs intended to improve conformability, fluid transfer, and handling characteristics during clinical use. The technology supports applications in wound care and surgical environments where enhanced drainage, flexibility, and tissue integration may help optimize placement and healing outcomes. - No. 30/010,026: FENESTRATED HUMAN PLACENTAL ALLOGRAFT
The patent is directed to fenestrated human placental allograft designs that facilitate fluid management. The design supports use in wound care and surgical settings where effective drainage is important. - No. 30/010,032: FENESTRATED HUMAN PLACENTAL ALLOGRAFT
The patent is directed to fenestrated allograft designs that preserve the structural integrity of amniotic and chorion tissues while supporting moisture management in complex wound environments. - No. 30/010,034: FENESTRATED HUMAN PLACENTAL ALLOGRAFT
The patent is directed to fenestrated allograft designs that enable controlled fluid passage that supports wound drainage and overall wound management across a range of applications.
The European patent covers:
- EP4442316A2: STERILE HUMAN PLACENTAL ALLOGRAFTS AND METHODS OF MAKING THEREOF
The patent is directed to sterile human placental allografts and proprietary processing methods designed to preserve the natural structural integrity and endogenous growth factors of placental tissue. The technology utilizes gentle cleaning, low-temperature dehydration, and low-dose e-beam sterilization techniques to create growth factor-rich allografts for wound healing, dental, cosmetic and surgical applications, while supporting improved tissue regeneration and reduced immunogenic response.
Want to keep up on regenerative medicine? Get the weekly newsletter here.
